This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated ki…

IgANC3GComplement-mediated Kidney Disease+2 more

~Estimated

~$10 – $8,750

ADARx Pharmaceuticals, Inc.NCT06989359

Phase 3

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (L…

IC-MPGN

~Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT05755386